German Cancer Consortium (DKTK) – A national consortium for translational cancer research

• Published in: Molecular oncology Vol. 13; no. 3; pp. 535 - 542
• Main Authors: Joos, Stefan, Nettelbeck, Dirk M., Reil‐Held, Anette, Engelmann, Katja, Moosmann, Alexandra, Eggert, Angelika, Hiddemann, Wolfgang, Krause, Mechthild, Peters, Christoph, Schuler, Martin, Schulze‐Osthoff, Klaus, Serve, Hubert, Wick, Wolfgang, Puchta, Josef, Baumann, Michael
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.03.2019; John Wiley and Sons Inc; Wiley
• Subjects: Biomarkers; Cancer; Cancer research; Career development; Consortia; Cooperation; Development and progression; Germany; Good Manufacturing Practice; Humans; Medical centers; Medical Oncology; Medical research; multisite cooperation; Neoplasms - therapy; Oncology, Experimental; personalized oncology; Physicians; research consortium; Review; Translation; translational cancer research; Translational Medical Research; Germany; research consortium; personalized oncology; multisite cooperation; Germany; translational cancer research
• ISSN: 1574-7891; 1878-0261
• DOI: 10.1002/1878-0261.12430

The German Cancer Consortium (‘Deutsches Konsortium für Translationale Krebsforschung’, DKTK) is a long‐term cancer consortium, bringing together the German Cancer Research Center (DKFZ), Germany's largest life science research center, and the leading University Medical Center‐based Comprehensive Cancer Centers (CCCs) at seven sites across Germany. DKTK was founded in 2012 following international peer review and has positioned itself since then as the leading network for translational cancer research in Germany. DKTK is long term funded by the German Ministry of Research and Education and the federal states of each DKTK partner site. DKTK acts at the interface between basic and clinical cancer research, one major focus being to generate suitable multisite cooperation structures and provide the basis for including higher numbers of patients and facilitate effective collaborative forward and reverse translational cancer research. The consortium addresses areas of high scientific and medical relevance and develops critical infrastructures, for example, for omics technologies, clinical and research big data exchange and analysis, imaging, and clinical grade drug manufacturing. Moreover, DKTK provides a very attractive environment for interdisciplinary and interinstitutional training and career development for clinician and medical scientists. Promising new cancer research findings need to reach clinical development as quickly as possible. Accelerating this process is the mission of the German Cancer Consortium (DKTK). By joining more than 20 research institutions and university hospitals at eight sites, the DKTK has created a unique framework for clinically‐oriented cancer research to make lasting improvements for cancer patients across Germany.